Patents by Inventor Aravinda K. CHAVALMANE

Aravinda K. CHAVALMANE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for managing neuroinflammation and neurodegeneration
    Patent number: 11324747
    Abstract: A method of inhibiting neuroinflammation in neuron surrounding cells, includes a step of treating the neuron surrounding cells with at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof, to inhibit the neuroinflammation. A method of managing neuroinflammation or neuroinflammation mediated neurodegenerative disease or disorder in a subject in need thereof, includes administering at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof to the subject. A composition includes at least one tyrosine kinase inhibitor or at least one sirtuin-2 inhibitor optionally along with pharmaceutically acceptable excipient.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: May 10, 2022
    Assignee: CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
    Inventors: Taslimarif Saiyed, Ravi Manjithaya, Murumalla Ravi Kumar, Suresh Santhi Natesan, Janhavi Pandurangi, Aravinda K. Chavalmane, Shashank Rai
  • METHODS AND COMPOSITIONS FOR MANAGING NEUROINFLAMMATION AND NEURODEGENERATION
    Publication number: 20190255054
    Abstract: A method of inhibiting neuroinflammation in neuron surrounding cells, includes a step of treating the neuron surrounding cells with at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof, to inhibit the neuroinflammation. A method of managing neuroinflammation or neuroinflammation mediated neurodegenerative disease or disorder in a subject in need thereof, includes administering at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof to the subject. A composition includes at least one tyrosine kinase inhibitor or at least one sirtuin-2 inhibitor optionally along with pharmaceutically acceptable excipient.
    Type: Application
    Filed: June 7, 2017
    Publication date: August 22, 2019
    Applicant: CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
    Inventors: Taslimarif SAIYED, Ravi MANJITHAYA, Murumalla RAVI KUMAR, Suresh Santhi NATESAN, Janhavi PANDURANGI, Aravinda K. CHAVALMANE, Shashank RAI